Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine With or Without Deferasirox in High Risk MDS
NCT02159040Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deferasirox in myelodysplastic syndrome (MDS), sponsored by Novartis. Started Sep 2014; status: terminated.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02159040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02159040.